Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Genetic Subtyping
- V600E, V600E2, V600D, V600K, V600R, and K601E in BRAF exon 15
- G466A, G466V, G469A, G469R, and G469V in BRAF exon 11
- G12A, G12C, G12D, G12R, G12S, G12V, G13A, G13C, G13D, G13R, G13S, G13V, and A18T in NRAS exon 2
- A59D, A59T, Q61Ht, Q61Hc, Q61K, Q61L, Q61P, and Q61R in NRAS exon 3
- K117Nc, K117Nt, A146T, and A146V in NRAS exon 4
2.3. Statistical Analysis
2.4. Ethical Permission
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Erdmann, F.; Lortet-Tieulent, J.; Schuz, J.; Zeeb, H.; Greinert, R.; Breitbart, E.W.; Bray, F. International trends in the incidence of malignant melanoma 1953–2008—Are recent generations at higher or lower risk? Int. J. Cancer 2013, 132, 385–400. [Google Scholar] [CrossRef]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Pineros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953. [Google Scholar] [CrossRef] [Green Version]
- Larkin, J.; Ascierto, P.A.; Dreno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014, 371, 1867–1876. [Google Scholar] [CrossRef] [Green Version]
- Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507–2516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723. [Google Scholar] [CrossRef]
- Shain, A.H.; Yeh, I.; Kovalyshyn, I.; Sriharan, A.; Talevich, E.; Gagnon, A.; Dummer, R.; North, J.; Pincus, L.; Ruben, B.; et al. The Genetic Evolution of Melanoma from Precursor Lesions. N. Engl. J. Med. 2015, 373, 1926–1936. [Google Scholar] [CrossRef]
- Griewank, K.G.; Schilling, B.; Scholz, S.L.; Metz, C.H.; Livingstone, E.; Sucker, A.; Moller, I.; Reis, H.; Franklin, C.; Cosgarea, I.; et al. Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. Eur. J. Cancer 2016, 57, 112–117. [Google Scholar] [CrossRef]
- Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [Google Scholar] [CrossRef]
- Platz, A.; Egyhazi, S.; Ringborg, U.; Hansson, J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol. 2008, 1, 395–405. [Google Scholar] [CrossRef] [Green Version]
- Liu, W.; Kelly, J.W.; Trivett, M.; Murray, W.K.; Dowling, J.P.; Wolfe, R.; Mason, G.; Magee, J.; Angel, C.; Dobrovic, A.; et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J. Investig. Dermatol. 2007, 127, 900–905. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milagre, C.; Dhomen, N.; Geyer, F.C.; Hayward, R.; Lambros, M.; Reis-Filho, J.S.; Marais, R. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res. 2010, 70, 5549–5557. [Google Scholar] [CrossRef] [Green Version]
- Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682–4689. [Google Scholar]
- Dummer, R.; Schadendorf, D.; Ascierto, P.A.; Arance, A.; Dutriaux, C.; Di Giacomo, A.M.; Rutkowski, P.; Del Vecchio, M.; Gutzmer, R.; Mandala, M.; et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017, 18, 435–445. [Google Scholar] [CrossRef]
- Heppt, M.V.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; et al. Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care. BMC Cancer 2017, 17, 536. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, A. Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis. Am. J. Clin. Dermatol. 2018, 19, 24–30. [Google Scholar] [CrossRef] [Green Version]
- Liszkay, G.; Orosz, Z.; Peley, G.; Csuka, O.; Plotar, V.; Sinkovics, I.; Banfalvi, T.; Fejos, Z.; Gilde, K.; Kasler, M. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res. 2005, 15, 509–513. [Google Scholar] [CrossRef] [PubMed]
- Smoller, B.R.; Gershenwald, J.E.; Scolye, R.A.; Brown, J.A.; Crowson, A.N.; Divaris, D.; Frishberg, D.P.; McNiff, J.M.; Phung, T.L.; Prieto, V.G.; et al. Protocol for the Examination of Specimens from Patients with Melanoma of the Skin (Version 4.0.1.0). Available online: https://documents.cap.org/protocols/cp-skin-melanoma-17protocol-4010.pdf (accessed on 29 June 2017).
- Jansen, L.; Nieweg, O.E.; Peterse, J.L.; Hoefnagel, C.A.; Olmos, R.A.; Kroon, B.B. Reliability of sentinel lymph node biopsy for staging melanoma. Br. J. Surg. 2000, 87, 484–489. [Google Scholar] [CrossRef]
- Morton, D.L.; Cochran, A.J.; Thompson, J.F.; Elashoff, R.; Essner, R.; Glass, E.C.; Mozzillo, N.; Nieweg, O.E.; Roses, D.F.; Hoekstra, H.J.; et al. Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann. Surg. 2005, 242, 302–311. [Google Scholar] [CrossRef]
- Morton, D.L.; Thompson, J.F.; Cochran, A.J.; Mozzillo, N.; Nieweg, O.E.; Roses, D.F.; Hoekstra, H.J.; Karakousis, C.P.; Puleo, C.A.; Coventry, B.J.; et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 2014, 370, 599–609. [Google Scholar] [CrossRef] [Green Version]
- Long, G.V.; Menzies, A.M.; Nagrial, A.M.; Haydu, L.E.; Hamilton, A.L.; Mann, G.J.; Hughes, T.M.; Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011, 29, 1239–1246. [Google Scholar] [CrossRef]
- Ekedahl, H.; Cirenajwis, H.; Harbst, K.; Carneiro, A.; Nielsen, K.; Olsson, H.; Lundgren, L.; Ingvar, C.; Jonsson, G. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br. J. Dermatol. 2013, 169, 1049–1055. [Google Scholar] [CrossRef]
- Carlino, M.S.; Haydu, L.E.; Kakavand, H.; Menzies, A.M.; Hamilton, A.L.; Yu, B.; Ng, C.C.; Cooper, W.A.; Thompson, J.F.; Kefford, R.F.; et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br. J. Cancer 2014, 111, 292–299. [Google Scholar] [CrossRef] [Green Version]
- Shinozaki, M.; O’Day, S.J.; Kitago, M.; Amersi, F.; Kuo, C.; Kim, J.; Wang, H.J.; Hoon, D.S. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 2007, 13, 2068–2074. [Google Scholar] [CrossRef] [Green Version]
- Ny, L.; Hernberg, M.; Nyakas, M.; Koivunen, J.; Oddershede, L.; Yoon, M.; Wang, X.; Guyot, P.; Geisler, J. BRAF mutational status as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis. Acta Oncol. 2020, 59, 833–844. [Google Scholar] [CrossRef] [Green Version]
- Akslen, L.A.; Angelini, S.; Straume, O.; Bachmann, I.M.; Molven, A.; Hemminki, K.; Kumar, R. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Investig. Dermatol. 2005, 125, 312–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ellerhorst, J.A.; Greene, V.R.; Ekmekcioglu, S.; Warneke, C.L.; Johnson, M.M.; Cooke, C.P.; Wang, L.E.; Prieto, V.G.; Gershenwald, J.E.; Wei, Q.; et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 2011, 17, 229–235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manninen, A.A.; Gardberg, M.; Juteau, S.; Ilmonen, S.; Jukonen, J.; Andersson, N.; Carpen, O. BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas. PLoS ONE 2019, 14, e0216043. [Google Scholar] [CrossRef] [PubMed]
- Adler, N.R.; Wolfe, R.; McArthur, G.A.; Kelly, J.W.; Haydon, A.; McLean, C.A.; Mar, V.J. Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. Br. J. Cancer 2018, 118, 1289–1295. [Google Scholar] [CrossRef]
- Pracht, M.; Mogha, A.; Lespagnol, A.; Fautrel, A.; Mouchet, N.; Le Gall, F.; Paumier, V.; Lefeuvre-Plesse, C.; Rioux-Leclerc, N.; Mosser, J.; et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J. Eur. Acad. Dermatol. Venereol. 2015, 8, 1530–1538. [Google Scholar] [CrossRef]
- Leonardi, G.C.; Candido, S.; Falzone, L.; Spandidos, D.A.; Libra, M. Cutaneous melanoma and the immunotherapy revolution (Review). Int. J. Oncol. 2020, 3, 609–618. [Google Scholar] [CrossRef]
- Griewank, K.G.; Murali, R.; Puig-Butille, J.A.; Schilling, B.; Livingstone, E.; Potrony, M.; Carrera, C.; Schimming, T.; Möller, I.; Schwamborn, M.; et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J. Natl. Cancer Inst. 2014, 9, dju246. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Values |
---|---|
All patients | 159 |
Age (year) (median, min; max) | 59 (18; 83) |
Follow-up time (month) (median, min; max) | 61 (1; 96) |
Gender | |
male | 71 (44.7%) |
female | 88 (55.3) |
Location | |
upper extremity | 35 (22%) |
lower extremity | 47 (29.6%) |
trunk | 77 (48.4%) |
Breslow (mm) (median, min; max) | 1.8 (0.51; 20) |
Breslow categories | |
I (≤1 mm) | 21 (13.2%) |
II (1.01–2.00 mm) | 65 (40.9%) |
III (2.01–4.00 mm) | 62 (39%) |
IV (>4 mm) | 11 (6.9%) |
Ulceration | |
no | 110 (69.2%) |
yes | 49 (30.8%) |
Histological subtype | |
SSM | 124 (78%) |
NM | 31 (19.5%) |
LMM | 1 (0.6%) |
ALM | 1 (0.6%) |
other | 2 (1.3%) |
Mitosis count (/mm2) (median, min; max) | 4 (0; 31) |
Invasion | |
no | 132 (83%) |
vascular | 11 (6.9% |
lymphatic | 11 (6.9% |
vascular and lymphatic | 2 (1.3%) |
perineural | 2 (1.3%) |
NA | 1 (0.6%) |
TIL | |
no | 73 (45.9%) |
yes | 86 (54.1) |
Regression | |
no | 79 (49.7%) |
early | 9 (5.7%) |
late, <75% | 50 (31.4%) |
late, ≥75% | 21 (13.2%) |
Mutation categories | |
double wild-type | 28 (17.6%) |
BRAF | 90 (56.6%) |
NRAS | 29 (18.2%) |
NA | 12 (7.5%) |
Sentinel status | |
negative | 130 (81.8%) |
positive | 29 (18.2) |
Characteristics | Sentinel Negative | Sentinel Positive | p (with Applied Statistics) |
---|---|---|---|
All patients | 130 | 29 | |
Age (year) (median, min; max) | 59.5 (18; 82) | 58 (32; 83) | 0.81 (Mann–Whitney) |
Gender | 0.208 (χ2) | ||
male | 55 (42.3%) | 16 (55.2%) | |
female | 75 (57.7%) | 13 (44.8%) | |
Location | 0.211 (χ2) | ||
upper extremity | 32 (24.6%) | 3 (10.3%) | |
lower extremity | 36 (27.7%) | 11 (37.9%) | |
trunk | 62 (47.7%) | 15 (51.7%) | |
Breslow (mm) (median, min; max) | 1.64 (0.51; 20) | 2.45 (0.79; 15) | 0.008 (Mann–Whitney) |
Ulceration | 0.007 (χ2) | ||
no | 96 (73.8%) | 14 (48.3%) | |
yes | 34 (26.2%) | 15 (51.7%) | |
Histological subtype | 0.177 (χ2) | ||
SSM | 104 (80%) | 20 (69%) | |
NM | 24 (18.5%) | 7 (24.1%) | |
other | 2 (1.5%) | 2 (6.9%) | |
Mitosis count (/mm2) (median, min; max) | 3 (0; 31) | 5 (1; 30) | 0.009 (Mann–Whitney) |
Invasion (all type) | 0.004 (χ2) | ||
no | 113 (86.7%) | 19 (65.5%) | |
yes | 16 (12.3%) | 10 (34.5%) | |
NA | 1 (0%) | 0 (0%) | |
TIL | 0.34 (χ2) | ||
no | 62 (47.7%) | 11 (37.9%) | |
yes | 68 (52.3%) | 18 (62.1%) | |
Regression | 0.873 (χ2) | ||
no | 63 (48.5%) | 16 (55.2%) | |
early | 7 (5.4%) | 2 (6.9%) | |
late, <75% | 42 (32.3%) | 8 (27.6%) | |
late, ≥75% | 18 (13.9%) | 3 (10.3%) | |
Mutation categories | 0.218 (χ2) | ||
double wild | 23 (17.7%) | 5 (17.2%) | |
BRAF | 71 (54.6%) | 19 (65.5%) | |
NRAS | 27 (20.8%) | 2 (6.9%) | |
NA | 9 (6.9%) | 3 (10.3%) |
Variable | OR (95% CI) | p |
---|---|---|
Age (≤59 vs. >59) | 0.744 (0.268–2.065) | 0.571 |
Gender (male vs. female) | 0.563 (0.213–1.492) | 0.248 |
Location (extremity vs. trunk) | 1.142 (0.402–3.236) | 0.804 |
Breslow (I–II vs. III–IV) | 4.222 (1.201–14.837) | 0.025 |
Ulceration (no vs. yes) | 1.203 (0.383–3.788) | 0.751 |
Mitosis (<4 vs. ≥4) | 1.904 (0.617–5.874) | 0.263 |
Invasion (no vs. yes) | 1.759 (0.547–5.655) | 0.343 |
TIL (no vs. yes) | 1.185 (0.442–3.175) | 0.736 |
BRAF (wild type vs. mutant) | 1.287 (0.35–4.73) | 0.704 |
NRAS (wild type vs. mutant) | 0.314 (0.046–2.145) | 0.237 |
Characteristics | Double Wild | BRAFmut | NRASmut | p (with Applied Statistics) |
---|---|---|---|---|
All patients | 28 | 90 | 29 | |
Age (year) (median, min; max) | 68 (19; 82) | 53 (23; 83) * | 66 (30; 81) | 0.001 (Kruskal–Wallis) |
Gender | 0.555 (χ2) | |||
male | 12 (42.9%) | 40 (44.4%) | 16 (55.2%) | |
female | 16 (57.1%) | 50 (55.6%) | 13 (44.8%) | |
Location | 0.116 (χ2) | |||
upper extremity | 8 (28.6%) | 16 (17.8%) | 8 (27.6%) | |
lower extremity | 11 (39.3%) | 28 (31.1%) | 4 (13.8%) | |
trunk | 9 (31.1%) | 46 (51.1%) | 17 (58.6%) | |
Breslow (mm) (median, min; max) | 1.675 (0.73; 20) | 1.64 (0.51; 15) | 2.72 (0.84; 8) * | 0.018 (Kruskal–Wallis) |
Ulceration | 0.534 (χ2) | |||
no | 21 (75%) | 64 (71.1%) | 18 (62.1%) | |
yes | 7 (25%) | 26 (28.9%) | 11 (37.9%) | |
Histological subtype | 0.244 (χ2) | |||
SSM | 23 (82.1%) | 72 (80%) | 20 (69%) | |
NM | 5 (17.9%) | 15 (16.7%) | 9 (24.1%) | |
other | 0 (0%) | 3 (3.3%) | 0 (0%) | |
Mitosis count (/mm2) (median min; max) | 3.5 (0; 26) | 3 (0; 24) | 4 (0; 31) | 0.319 (Kruskal-Wallis) |
Invasion (all type) | 0.193 (χ2) | |||
no | 18 (64.3%) | 78 (86.7%) | 27 (93.1%) | |
yes | 10 (35.7%) | 12 (13.3%) | 1 (3.4%) | |
NA | 0 (0%) | 0 (0%) | 1 (3.4%) | |
TIL | 0.474 (χ2) | |||
no | 13 (46.4%) | 38 (42.2%) | 16 (55.2%) | |
yes | 15 (53.6%) | 52 (67.8%) | 13 (44.8%) | |
Regression | 0.873 (χ2) | |||
no | 15 (53.6%) | 42 (46.7%) | 16 (55.2%) | |
early | 2 (7.1%) | 6 (6.7%) | 0 (0%) | |
late <75% | 8 (28.6%) | 30 (33.3%) | 10 (34.5%) | |
late ≥75% | 3 (10.7%) | 12 (13.3%) | 3 (10.3%) | |
Sentinel status | 0.218 (χ2) | |||
negative | 23 (82.1%) | 71 (78.9%) | 27 (93.1%) | |
positive | 5 (17.9%) | 19 (21.1%) | 2 (6.9%) |
Parameters of Patients | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
RR (95% CI) | p | RR (95% CI) | p | |
PFS | ||||
Age | 1.023 (0.996–1.051) | 0.089 | 1.026 (0.995–1.058) | 0.098 |
Gender (male vs. female) | 1.084 (0.526–2.232) | 0.827 | 1.259 (0.577–2.743) | 0.563 |
Location (extremity vs. trunk) | 0.786 (0.382–1.618) | 0.513 | 1.117 (0.702–1.778) | 0.641 |
Breslow thickness | 1.206 (1.11–1.311) | <10−3 | 1.141 (1.018–1.28) | 0.024 |
Ulceration (no vs. yes) | 2.883 (1.406–5.912) | 0.004 | 1.082 (0.398–2.937) | 0.877 |
Mitosis number | 1.081 (1.035–1.129) | <10−3 | 1.058 (0.997–1.123) | 0.062 |
Invasion (no vs. yes) | 2.534 (1.157–5.549) | 0.02 | 1.8 (0.713–4.543) | 0.111 |
TIL (no vs. yes) | 1.018 (0.882–1.175) | 0.812 | 1.07 (0.915–1.251) | 0.213 |
NRAS (wild-type vs. mutant) | 1.479 (1.003–2.18) | 0.048 | 1.887 (1.008–3.53) | 0.047 |
BRAF (wild-type vs. mutant) | 0.577 (0.275–1.214) | 0.148 | 0.719 (0.227–2.277) | 0.575 |
Sentinel status (negative vs. positive) | 3.315 (1.595–6.89) | 0.001 | 3.301 (1.424–7.654) | 0.005 |
DMFS | ||||
Age | 1.04 (1.005–1.075) | 0.023 | 1.047 (1.007–1.087) | 0.019 |
Gender (male vs. female) | 1.197 (0.511–2.8) | 0.679 | 1.39 (0.56–3.45) | 0.477 |
Location (extremity vs. trunk) | 0.873 (0.377–2.02) | 0.75 | 0.979 (0.555–1.728) | 0.942 |
Breslow thickness | 1.223 (1.12–1.333) | <10−3 | 1.178 (1.039–1.336) | 0.011 |
Ulceration (no vs. yes) | 2.937 (1.268–6.802) | 0.012 | 0.837 (0.236–2.964) | 0.782 |
Mitosis number | 1.089 (1.037–1.423) | <10−3 | 1.07 (0.999–1.146) | 0.054 |
Invasion (no vs. yes) | 4.143 (1.765–9.728) | 0.001 | 3.255 (1.09–9.723) | 0.034 |
TIL (no vs. yes) | 0.966 (0.815–1.145) | 0.687 | 1.046 (0.864–1.265) | 0.647 |
NRAS (wild-type vs. mutant) | 1.439 (0.911–2.274) | 0.119 | 2.034 (0.97–4.265) | 0.06 |
BRAF (wild-type vs. mutant) | 0.569 (0.239–1.356) | 0.203 | 0.643 (0.174–2.379) | 0.508 |
Sentinel status (negative vs. positive) | 3.288 (1.404–7.698) | 0.006 | 2.929 (1.087–7.892) | 0.034 |
DSS | ||||
Age | 1.041 (1–1.084) | 0.051 | 1.047 (0.999–1.097) | 0.056 |
Gender (male vs. female) | 1.785 (0.62–5.142) | 0.283 | 2.055 (0.629–6.713) | 0.233 |
Location (extremity vs. trunk) | 0.802 (0.299–2.154) | 0.662 | 0.789 (0.396–1.571) | 0.499 |
Breslow thickness | 1.283 (1.161–1.418) | <10−3 | 1.294 (1.127–1.485) | <10−3 |
Ulceration (no vs. yes) | 3.089 (1.5–8.3) | 0.025 | 0.577 (0.113–2.948) | 0.509 |
Mitosis number | 1.108 (1.051–1.169) | <10−3 | 1.089 (1.006–1.177) | 0.034 |
Invasion (no vs. yes) | 4.346 (1.613–11.708) | 0.004 | 3.485 (0.918–13.232) | 0.067 |
TIL (no vs. yes) | 1.032 (0.848–1.256) | 0.751 | 1.086 (0.87–1.357) | 0.466 |
NRAS (wild-type vs. mutant) | 1.407 (0.821–2.41) | 0.214 | 1.869 (0.757–4.615) | 0.175 |
BRAF (wild-type vs. mutant) | 0.544 (0.196–1.508) | 0.242 | 0.771 (0.146–4.077) | 0.759 |
Sentinel status (negative vs. positive) | 2.593 (0.942–7.136) | 0.065 | 1.774 (0.538–5.85) | 0.346 |
OS | ||||
Age | 1.061 (1.026–1.097) | <10−3 | 1.068 (1.027–1.11) | <10−3 |
Gender (male vs. female) | 0.741 (0.357–1.536) | 0.42 | 1.17 (0.523–2.614) | 0.703 |
Location (extremity vs. trunk) | 0.961 (0.464–1.992) | 0.915 | 0.743 (0.445–1.241) | 0.256 |
Breslow thickness | 1.296 (1.889–1.413) | <10−3 | 1.246 (1.112–1.397) | <10−3 |
Ulceration (no vs. yes) | 3.95 (1.865–8.366) | <10−3 | 1.558 (0.541–4.482) | 0.411 |
Mitosis number | 1.098 (1.052–1.456) | <10−3 | 1.057 (0.995–1.123) | 0.07 |
Invasion (no vs. yes) | 2.165 (0.961–4.875) | 0.062 | 1.399 (0.518–3.782) | 0.508 |
TIL (no vs. yes) | 1.012 (0.875–1.171) | 0.87 | 1.06 (0.905–1.241) | 0.472 |
NRAS (wild-type vs. mutant) | 1.52 (1.026–2.253) | 0.037 | 1.327 (0.704–2.5) | 0.382 |
BRAF (wild-type vs. mutant) | 0.456 (0.212–0.981) | 0.045 | 1068 (0.336–3.398) | 0.911 |
Sentinel status (negative vs. positive) | 1.72 (0.761–3.89) | 0.193 | 1.594 (0.641–3.962) | 0.315 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liszkay, G.; Mátrai, Z.; Czirbesz, K.; Jani, N.; Bencze, E.; Kenessey, I. Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study. Cancers 2021, 13, 3302. https://doi.org/10.3390/cancers13133302
Liszkay G, Mátrai Z, Czirbesz K, Jani N, Bencze E, Kenessey I. Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study. Cancers. 2021; 13(13):3302. https://doi.org/10.3390/cancers13133302
Chicago/Turabian StyleLiszkay, Gabriella, Zoltán Mátrai, Kata Czirbesz, Nóra Jani, Eszter Bencze, and István Kenessey. 2021. "Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study" Cancers 13, no. 13: 3302. https://doi.org/10.3390/cancers13133302